All Rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The biggest head-to-head comparison of anti-HIV drugs to date shows that a first-line regimen containing Sustiva and Combivir, which contains 3TC and AZT, works better, longer, and more quickly than other antiretroviral combinations. The cocktail is also easy to take'just one pill in the morning and two at night'and preserves protease inhibitors for later use, according to Jose Zuniga, president of the International Association of Physicians in AIDS Care. The study of nearly 1,000 patients beginning antiretroviral therapy showed that about only 10% of those on the Sustiva-Combivir cocktail for 11 months experienced rising viral loads, falling CD4-cell counts, or severe drug-related side effects, compared with 30% to 40% of those on other three-drug regimens. A four-drug cocktail also proved no more effective than the Sustiva-Combivir combination.
From our Sponsors
Most Popular
The road to U=U: How science has been liberating HIV+ people for a decade
Newly diagnosed with HIV? Advocates share their best advice for seeking treatment
How to find an HIV-competent healthcare provider, according to advocates
Latest Stories
A New Once-Daily Pill to Treat HIV Just Got the FDA’s Green Light
Why affirming faith communities belong in the fight to end HIV
Navigating a new HIV diagnosis? Advocates say community is key
Gay Wine Weekend toasts 15 years of raising funds for HIV
A new HIV diagnosis doesn't have to be nerve-wracking. Advocates share their advice
Zero HIV Stigma Day: The epidemic we still choose to ignore
National HIV Prevention Day: Awareness is my superpower
Federal court clarifies that people with HIV can join the military again
Can a single infusion of immune cells suppress HIV for years?
National HIV advocacy group's CEO rejects claims of crisis
Beyond awareness: How youth leadership is reshaping the HIV response
Saving public health? AIDS United's new CEO has a plan
Struggling with daily HIV meds? Monthly shots may be the answer
Trending stories
Recommended Stories for You


































































